 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Benitec Reacquires HCV Program in Tacere Therapeutics Buyout
October 11, 2012
Benitec Reacquires HCV Program in Tacere Therapeutics Buyout
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UC, San Diego Selected as Site for Benitec HCV Drug Trial
April 18, 2013 / Gene Silencing News - Benitec Raises Funds for HCV Trial through Private Placement
March 7, 2013 / Gene Silencing News - Benitec Looks to Outlicense IP While Avoiding Litigation Mistakes of Its Past
November 8, 2012 / Gene Silencing News - Benitec Provides Pipeline Update Following Tacere Acquisition
October 18, 2012 / Gene Silencing News - Benitec Wins Chinese Patent on Expressed RNAi HCV Therapy
October 11, 2012 / Gene Silencing News